NLS Pharmaceutics ( (NLSP) ) has issued an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NLS Pharmaceutics and Kadimastem have announced the initial closing of a $500,000 fundraising effort, part of a larger $1 million initiative aimed at facilitating a proposed merger between the two companies. This merger seeks to create a Nasdaq-traded biotechnology company with advanced-stage product candidates, enhancing strategic positioning in the biotechnology sector and unlocking new opportunities for stakeholders.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and complex central nervous system disorders. Kadimastem Ltd. is an Israeli clinical-stage cell therapy company developing allogeneic cell products for neurodegenerative diseases and diabetes.
YTD Price Performance: -5.50%
Average Trading Volume: 748,627
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.17M
See more insights into NLSP stock on TipRanks’ Stock Analysis page.